» Articles » PMID: 28458469

TM4SF5-Mediated Roles in the Development of Fibrotic Phenotypes

Overview
Publisher Wiley
Specialties Biochemistry
Pathology
Date 2017 May 2
PMID 28458469
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Transmembrane 4 L six family member 5 (TM4SF5) can form tetraspanin-enriched microdomains (TERMs) on the cell's surface. TERMs contain protein-protein complexes comprised of tetraspanins, growth factor receptors, and integrins. These complexes regulate communication between extracellular and intracellular spaces to control diverse cellular functions. TM4SF5 influences the epithelial-mesenchymal transition (EMT), aberrant multilayer cellular growth, drug resistance, enhanced migration and invasion, circulation through the bloodstream, tumor-initiation property, metastasis, and muscle development in zebrafish. Here, current data on TM4SF5's roles in the development of fibrotic phenotypes are reviewed. TM4SF5 is induced by transforming growth factor 1 (TGF1) signaling via a collaboration with epidermal growth factor receptor (EGFR) activation. TM4SF5, by itself or in concert with other receptors, transduces signals intracellularly. In hepatocytes, TM4SF5 expression regulates cell cycle progression, migration, and expression of extracellular matrix components. In CCl-treated mice, TM4SF5, -smooth muscle actin (-SMA), and collagen I expression are observed together along the fibrotic septa regions of the liver. These fibrotic phenotypes are diminished by anti-TM4SF5 reagents, such as a specific small compound [TSAHC, 4'-(-toluenesulfonylamido)-4-hydroxychalcone] or a chimeric antibody. This review discusses the antifibrotic strategies that target TM4SF5 and its associated protein networks that regulate the intracellular signaling necessary for fibrotic functions of hepatocytes.

Citing Articles

Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance.

Rahim N, Wu Y, Sim M, Velaga A, Bonam S, Gopinath S Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678607 PMC: 9867095. DOI: 10.3390/ph16010110.


TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases.

Kim J, Kim E, Lee J Int J Mol Sci. 2022; 23(15).

PMID: 35955521 PMC: 9369364. DOI: 10.3390/ijms23158387.


TM4SF5 Knockout Protects Mice From Diet-Induced Obesity Partly by Regulating Autophagy in Adipose Tissue.

Choi C, Son Y, Kim J, Cho Y, Saha A, Kim M Diabetes. 2021; 70(9):2000-2013.

PMID: 34187836 PMC: 8576418. DOI: 10.2337/db21-0145.


Von Willebrand factor protects against acute CCl-induced hepatotoxicity through phospho-p38 MAPK signaling pathway inhibition.

Sun H, Chen J, Zhang H, Ni B, van Velkinburgh J, Liu Y Immunol Res. 2017; 65(5):1046-1058.

PMID: 28868583 DOI: 10.1007/s12026-017-8946-7.

References
1.
Gressner A, Weiskirchen R . Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006; 10(1):76-99. PMC: 3933103. DOI: 10.1111/j.1582-4934.2006.tb00292.x. View

2.
Lee D, Na J, Ryu J, Kim H, Nam S, Kang M . Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells. Hepatology. 2015; 61(6):1978-97. DOI: 10.1002/hep.27721. View

3.
Lee S, Ryu H, Kim Y, Choi S, Lee M, Kwak T . Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology. 2009; 49(4):1316-25. DOI: 10.1002/hep.22777. View

4.
Kang M, Jeong S, Park S, Lee H, Kim H, Park K . Antagonistic regulation of transmembrane 4 L6 family member 5 attenuates fibrotic phenotypes in CCl(4) -treated mice. FEBS J. 2011; 279(4):625-35. DOI: 10.1111/j.1742-4658.2011.08452.x. View

5.
Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot R, Jove R . Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998; 18(5):2545-52. PMC: 110634. DOI: 10.1128/MCB.18.5.2545. View